69049-74-7

Basic information

• Product Name: NEDOCROMIL SODIUM
• Synonyms: NEDOCROMIL DISODIUM SALT;[9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]quinoline]-2,8-dicarboxylic acid disodium salt;Nedocromil sodium;4H-Pyrano(3,2-G)quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-, disodium salt;Alocril;Tilade;Unii-et8if4ks1t;Tayled
• CAS NO: 69049-74-7
• Molecular Formula: C₁₉H₁₅NO₇*2Na
• Molecular Weight: 415.3
• Product Categories: API
• Mol File: 69049-74-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 645.5 °C at 760 mmHg
• Flash Point: 344.2°C
• Appearance: , white to beige to brown/
• Vapor Pressure: 1.52E-17mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: H2O: soluble20mg/mL, clear
• CAS DataBase Reference: NEDOCROMIL SODIUM(CAS DataBase Reference)
• NIST Chemistry Reference: NEDOCROMIL SODIUM(69049-74-7)
• EPA Substance Registry System: NEDOCROMIL SODIUM(69049-74-7)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 69049-74-7(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 69049-74-7 differently. You can refer to the following data:
1. Nedocromil sodium is an antiallergic agent with broader mast cell stabilizing properties than related cromolyn sodium. Administered as an aerosol, it is useful in the treatment of bronchial asthma and related diseases.
2. Nedocromil is a mast cell stabilizer. It inhibits IgE-induced histamine release from rat peritoneal mast cells cocultured with 3T3 cells (MC/3T3) and preincubated with IL-2 when used at a concentration of 10 μM in acute (1 hour) and chronic (5 days) assays. Nedocromil prevents early- and late-phase bronchoconstriction in a guinea pig model of asthma induced by ovalbumin. It also prevents conjunctival edema and erythema and reduces mast cell degranulation in a rat model of conjunctivitis when administered intravenously at a dose of 2 mg/kg. Formulations containing nedocromil have been used in the treatment of allergic conjunctivitis and asthma.

Originator

Fisons (United Kingdom)

Uses

Different sources of media describe the Uses of 69049-74-7 differently. You can refer to the following data:
1. Anti-allergic (prophylactic.
2. Nedocromil Sodium (Technical Grade) is a medication considered as mast cell stabilizer which act to prevent wheezing, shortness of breath, and other breathing problems caused by asthma.

Indications

nedocromil sodium(Tilade) is chemically related drugs called chromones that is used for the prophylaxis of mild or moderate asthma. It is administered by inhalation and has very good safety profiles, making them particularly useful in treating children.

Brand name

Alocril (Allergan); Tilade (King); Tilade (Sanofi Aventis).

Therapeutic Function

Antiallergic, Anti-asthmatic

General Description

Nedocromil sodium, disodium9-ethyl-6, 9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3, 2-g]quinoline-2,8-dicarboxylate (Tilade), is structurally relatedto cromolyn and displays similar, but broader, pharmacologicalactions. It was available as an aerosol in ametered-dose inhaler for asthma treatment, and currently remainsavailable as ophthalmic solution for the treatmentof itching associated with allergic conjunctivitis. The inhalationformulation was marketed for maintenance therapyin the management of patients with mild-to-moderatebronchial asthma, but since has been withdrawn.

Pharmacokinetics

Nedocromil sodium was developed by changing the furan ring of khellin to a piperidinone ring. In vitro, nedocromil sodium inhibits the release of inflammatory response mediators from a variety of cells, including neutrophils, mast cells, macrophages, and platelets. Inhaled nedocromil sodium is poorly absorbed into the systemic circulation, with approximately 3% of an inhaled dose excreted in the urine during the first 6 hours after administration. Only 2% of orally dosed nedocromil sodium is bioavailable, 89% of which is protein bound. When administered IV, nedocromil sodium is not metabolized and is excreted unchanged in the bile and the urine. Nedocromil sodium is available in aerosol canisters for oral inhalation via a mouthpiece.

Clinical Use

nedocromil sodium is used almost exclusively for the prophylactic treatment of mild to moderate asthma and should not be used for the control of acute bronchospasm. This agent is effective in about 60 to 70% of children and adolescents with asthma. Unfortunately, there is no reliable means to predict which patients will respond.It is less effective in older patients and in patients with severe asthma. It may take up to 4 to 6 weeks of treatment for cromolyn sodium to be effective in chronic asthma, but it is effective after a single dose in exercise-induced asthma. With respect to clinical efficacy, cromolyn sodium and nedocromil sodium do not differ in a substantial way.

Side effects

nedocromil sodium is the least toxic of available therapies for asthma. Adverse reactions are rare and generally minor. Those occurring in fewer than 1 in 10,000 patients include transient bronchospasm, cough or wheezing, dryness of throat, laryngeal edema, swollen parotid gland, angioedema, joint swelling and pain, dizziness, dysuria, nausea, headache, nasal congestion, rash, and urticaria.

InChI:InChI=1/C19H17NO7.2Na/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11;;/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26);;/q;2*+1/p-2

Upstream product

• 69049-72-5 Diethyl 9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyrano<3,2-g>quinoline-2,8-dicarboxylate 
• 69049-70-3 Methyl 6-acetyl-1-ethyl-7-hydroxy-4-oxo-8-propyl-4H-quinoline-2-carboxylate 
• 588-16-9 m-methoxyacetanilide 
• 98331-45-4 3-(N-acetyl-N-ethylamino)phenol 
• 98331-43-2 N-ethyl-N-(3-methoxyphenyl)acetamide 
• 98331-47-6 3-(N-ethylacetamido)phenyl acetate 
• 69049-68-9 4-N-Ethylamino-3-propyl-2-hydroxyacetophenone 
• 69049-62-3 N-(4-Acetyl-3-hydroxy-phenyl)-N-ethyl-acetamide 
• 69049-63-4 N-(4-Acetyl-3-allyloxy-phenyl)-N-ethyl-acetamide 
• 69049-64-5 N-(4-Acetyl-2-allyl-3-hydroxy-phenyl)-N-ethyl-acetamide 
• 69049-66-7 N-(4-Acetyl-3-hydroxy-2-propyl-phenyl)-N-ethyl-acetamide 

Relevant articles and documents

New Antiallergic Pyranoquinoline-2,8-dicarboxylic Acids with Potential for the Topical Treatment of Asthma

A nimber of antiallergic pyranoquinolinedicarboxylic acid derivatives with potential for the topical treatment of asthma have been synthesized.All the compounds have been evaluated against rat passive cutaneous anaphylaxis and in a dog hypotension screen.This is the first detailed description of the application of the latter screen for the identification of antiallergic agents.Two compounds, disodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyranoquinoline-2,8-dicarboxylate (86) and disodium 6-(methylamino)-4-oxo-10-propyl-4H-pyranoquinoline-2,8-dicarboxylate (72), were selected and further evaluated for their ability to induce phosphorylation of a 78000 molecular weight protein associated with the rat peritoneal mast cell.Their ability to inhibit histamine release from these cells and from a mucosal mast cell preparation has also been evaluated.These compounds, nedocromil sodium (TILADE 86) and minocromil (the free acid of 72), are at present undergoing therapeutic evaluation.The rationale for the screening procedure and the relevance of the second carboxylic acid function of these dibasic acids to receptor binding are discussed.